Lee v. EUSA Pharma US LLC

CourtDistrict Court, E.D. Michigan
DecidedJanuary 23, 2024
Docket2:22-cv-11145
StatusUnknown

This text of Lee v. EUSA Pharma US LLC (Lee v. EUSA Pharma US LLC) is published on Counsel Stack Legal Research, covering District Court, E.D. Michigan primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lee v. EUSA Pharma US LLC, (E.D. Mich. 2024).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION

GEORGE LEE,

Plaintiffs, Case No. 2:22-cv-11145 District Judge Paul D. Borman

Magistrate Judge Anthony P. Patti v.

EUSA PHARMA US LLC and RECORDATI RARE DISEASES, INC.,

Defendants. ___________________________________/ ORDER AFTER IN CAMERA REVIEW I. Procedural and Factual Background On November 10, 2023, Plaintiff moved to compel certain discovery from Defendant. (ECF No. 42.) That motion asked the Court to compel answers to Plaintiff’s Interrogatory No. 9, regarding actions taken with respect to Plaintiff’s grievance (id., PageID.512-517), clarifying in the joint statement of unresolved issues that, “[t]here is also a corresponding request for production[,]” (ECF No. 49, PageID.821). The Court held a hearing on December 13, 2023, deciding most of the issues Plaintiff raised in the motion, but retaining under advisement the issue of documents related to a pre-lawsuit investigation conducted by the Jackson Lewis

law firm, over which Defendant asserts attorney-client privilege and work product doctrine protection. Specifically, the resulting Order states: Taking into consideration Affirmative Defense No. 8 (ECF No. 22, PageID.285), several of Plaintiff’s attachments to his motion (ECF Nos. 42-4, 42-5, 42-6, 42-7), and Plaintiff’s submission of a May 23, 2022 letter from Attorneys Patrice C. Dixon and Bert H. Ware to Plaintiff’s counsel (ECF No. 50), the Court TAKES UNDER ADVISEMENT its ruling as to RFP No. 11, namely whether Defendant must produce copies of any interviews or recordings thereof. No later than Wednesday, December 20, 2023, Defendant SHALL email Judge Patti’s Case Manager to provide the Court with copies of the letter of engagement between EUSA Pharma and Jackson Lewis PC, as well as the resulting report, for in camera review, after which the Court will issue its ruling on RFP No. 11. Meanwhile, Defendant SHALL answer Interrogatory No. 9, separately answering Subparts 9(a)-9(h), under oath and must identify each of the approximately twelve (12) interviewees, so that, in the event the Court concludes related materials need not be produced in response to RFP No. 11, Plaintiff at least will know who was interviewed. And, although not mentioned from the bench, Plaintiff is given leave under Fed. R. Civ. P. 30(a)(2)(A)(i) to depose all such interviewees, even if the total number of witnesses deposed exceeds ten in number, so long as the total number of depositions taken by Plaintiff does not exceed fifteen. Further, regardless of what the Court concludes as to RFP No. 11, Defendant SHALL produce any statements that were made by a witness under oath (or by way of declaration under penalty of perjury), whether written or recorded. (ECF No. 51, PageID.828-829 (emphases in original).) Subsequently, on December 27, 2023 and December 28, 2023, the Court issued additional text orders, each requiring Defendant to produce further information. In compliance with these orders, Defendant has now clarified that designations at the top of each page of the engagement letter and investigative

report provided to the Court for its in camera inspection – indicating that they were “privileged and confidential attorney-client communication attorney work product” and (with respect to the engagement letter only) “prepared in anticipation of future

litigation” – have appeared on these documents since their creation, i.e., they were not added as the documents were being prepared for review by the Court. (ECF No. 58.) Defendant has also verified that “neither Bert Ware nor Patrice Dickson [sic] [the attorneys who conducted the investigation and prepared the report] are

referred to in Defendant’s initial disclosures.” (ECF No. 59.) The Court has now completed its in camera inspection, reaches the following conclusions, and makes the following rulings.

II. The Jackson Lewis Firm Preliminarily, the Court notes that the focus of Plaintiff’s motion was obtaining answers to Interrogatory No. 9, which the Court in fact ordered (see ECF No. 51, PageID.829), without discussion of the corollary Request to Produce No.

11 until his brief reference to it in the Joint Statement (see ECF No. 49, PageID.820). Oral argument further clarified the focus of the requested ruling, which the Court identified as the narrow issue of “whether Defendant must

produce copies of any interviews or recordings thereof.” (ECF No. 51, PageID.828.) Informed by its in camera review of the Jackson Lewis engagement letter and the resulting investigative report, the Court SUSTAINS in large part

Defendant’s objection to producing documents relating to the investigation, based on the attorney-client privilege and work product doctrine. A. Defendant’s Engagement of Jackson Lewis

The Court finds that Defendant’s retention and engagement of Jackson Lewis, an outside law firm, to conduct an “impartial workplace investigation concerning allegations raised by Kevin Davis and George Lee” was done in anticipation of litigation. On February 24, 2022, Plaintiff emailed a “Statement of

Grievance” to Defendant, in which he, inter alia, questioned the evaluation of his performance, described his work environment as “toxic[,]” stated that he “felt bullied, harassed and my job status repeatedly threatened[,]” and felt that he was

“singled out and treated negatively” and also that his “opinion is devalued and ignored.” (ECF No. 42-4, PageID.559.) Plaintiff further rhetorically queried, “[i]sn’t it interesting this is also happening to the only other African American KAM in our sales force who is also 100% to goal?” (Id.) Of particular

significance is Plaintiff’s penultimate line before closing: “At this point, it is my hope we can resolve this internally, without retaliation, but I am not adverse to involving outside counsel.” (Id. (emphasis added).) This threat to bring in outside

counsel clearly elevated the situation to one in which litigation could reasonably be anticipated, and, in fact, was reasonably anticipated. In its immediate response to the grievance, Defendant communicated that it was “in the process of identifying

an outside investigator to investigate your concerns[.]” (Id., PageID.558.) By March 4, 2022, roughly ten days later, Defendant retained Jackson Lewis (now its litigation counsel of record) as its outside counsel to conduct the above-

referenced investigation. The services covered by that engagement were, per the engagement letter reviewed by the Court, “being provided to enable EUSA’s in- house and outside counsel to render legal advice to the company with respect to the subject matter of the Investigation.” The scope of the engagement included

making recommendations for eliminating and/or mitigating risks associated with certain employment practices, if they existed. Jackson Lewis’s services are referred to in various places as “representation.” Communications under the

engagement were to be confidential and included certain advice regarding preservation of evidence and litigation holds. Tellingly, five days after the engagement, on March 8, 2022, Defendant sent an email to Plaintiff, clearly in anticipation of litigation, titled “INVESTIGATION/LITIGATION HOLD

NOTICE AND DIRECTIVE TO PRESERVE PAPER RECORDS AND ELECTRONIC DATA[,]” specifically directing Plaintiff to “take the affirmative steps described in this Notice to preserve both hard-copy paper documents and ESI relevant to this investigation and that are in your custody or control.” (ECF No. 42-5 (emphasis and capitalization in the original).)

B. Investigation and Report Jackson Lewis’s report was not completed until May 13, 2022, well after the assertion of a litigation hold.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hickman v. Taylor
329 U.S. 495 (Supreme Court, 1947)
United States v. Nobles
422 U.S. 225 (Supreme Court, 1975)
Upjohn Co. v. United States
449 U.S. 383 (Supreme Court, 1981)
In Re Perrigo Company
128 F.3d 430 (Sixth Circuit, 1997)
Hickman v. Taylor
153 F.2d 212 (Third Circuit, 1945)
Harding v. Dana Transport, Inc.
914 F. Supp. 1084 (D. New Jersey, 1996)
Schipp Ex Rel. Estate of Neufelder v. General Motors Corp.
457 F. Supp. 2d 917 (E.D. Arkansas, 2006)
In Re: Kellogg Brown & Root, Inc.
756 F.3d 754 (D.C. Circuit, 2014)
United States v. Roxworthy
457 F.3d 590 (Sixth Circuit, 2006)
In re General Motors LLC Ignition Switch Litigation
80 F. Supp. 3d 521 (S.D. New York, 2015)
Volpe v. US Airways, Inc.
184 F.R.D. 672 (M.D. Florida, 1998)
American Standard, Inc. v. Bendix Corp.
71 F.R.D. 443 (W.D. Missouri, 1976)
Wilson v. Stroh Companies, Inc.
952 F.2d 942 (Sixth Circuit, 1992)
Massachusetts v. First National Supermarkets, Inc.
112 F.R.D. 149 (D. Massachusetts, 1986)
Ryall v. Appleton Electric Co.
153 F.R.D. 660 (D. Colorado, 1994)

Cite This Page — Counsel Stack

Bluebook (online)
Lee v. EUSA Pharma US LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lee-v-eusa-pharma-us-llc-mied-2024.